Earnings
Home›Earnings›Guidance›Thermo Fisher reports stronger Q2 growth and raises gu…
Thermo Fisher reports stronger Q2 growth and raises guidance
Thermo Fisher said fiscal Q2 revenue rose 10% to $11.99 billion, and it pointed to improving customer activity across pharma and biotech markets.
Thermo Fisher Scientific and Danaher are competing life sciences tools companies, and both posted better-than-expected second-quarter results, according to Yahoo Finance. The article characterizes Thermo Fisher's demand recovery as broad-based, while it describes Danaher's rebound as more uneven.
Thermo Fisher reported fiscal Q2 2026 revenue of $11.99 billion, up 10% year over year, with GAAP diluted EPS rising 9% to $4.68 and adjusted EPS increasing 13% to $6.03. The company also raised guidance, with management highlighting improving customer activity across pharmaceutical and biotechnology markets.
The piece adds that multiple operating segments returned to healthy growth, reinforcing the idea that the recovery is driven across several business lines. In particular, Thermo Fisher's Life Sciences Solutions segment showed reported revenue up 13% year over year, with organic revenue rising 3%, led by continued strength in its high-margin bioproduction business.
Yahoo Finance also flags a key bright spot for Thermo Fisher, saying its Analytical Instruments unit returned to growth after roughly two years of weak demand as biotechnology funding slowed. The article notes that while one quarter does not confirm a sustained trend, continued improvement in that segment would suggest laboratory spending is normalizing.